Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) AI-Powered Stock Analysis
See how Biodexa Pharmaceuticals Plc scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
BDRX●NASDAQ
HealthcareBiotechnology
$1.30
$0.64(96.94%)
U.S. Market opens in NaNh NaNm
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full DisclaimerBiodexa Pharmaceuticals Plc (NASDAQ: BDRX) Stock Overall Grade
Biodexa Pharmaceuticals Plc's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Biodexa Pharmaceuticals Plc's overall NASDAQ stock rating.
Forecast
C+Score
55/100Financial Growth
AScore
80/100Fundamental Growth
DScore
35/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
97/100Analyst Consensus
C+Score
50/100Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) AI-Powered Stock Analysis
On the NASDAQ, BDRX demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (35/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (50/100, C+) suggests High divergence in outlook.(NASDAQ: BDRX) Component Analysis Explained
Understand the key factors behind each Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) stock grade, including financials, comparisons, and forecasts.